ResMed Inc. Chairman and CEO Michael J. Farrell filed a Form 4 on November 13, 2026, reporting three dispositions of ResMed common stock on November 11, 2026, each representing shares withheld by the issuer to cover tax obligations upon the vesting of Restricted Stock Units.

Key Highlights

  • Three tax-withholding dispositions: Farrell disposed of 3,465.749 shares, 2,209.793 shares, and 2,435.843 shares to ResMed on November 11, 2026, all at $234.11 per share.
  • RSU grant sources: The three dispositions relate to RSUs originally granted on November 16, 2023; November 20, 2024; and November 20, 2025, respectively, according to the filing.
  • Transaction code F: All three transactions are coded "F," indicating disposition to the issuer for tax withholding purposes.
  • Remaining direct ownership: Following the transactions, Farrell directly held 471,774 shares of ResMed common stock, per the filing.
  • Indirect holdings: The filing also reports 2,090 shares held indirectly through the Lisette and Michael Farrell Family Trust.
  • ESPP note: The filing states that the 471,774 direct share total includes 82.2684 shares purchased on October 30, 2026 through the ResMed Employee Stock Purchase Plan.

Farrell's November 11 RSU Vesting Withholding Transactions at ResMed

According to the Form 4 filed with the SEC on November 13, 2026, Michael J. Farrell, Chairman and CEO of ResMed Inc. (NYSE:RMD), reported three separate dispositions of ResMed common stock on November 11, 2026. Each disposition was coded "F," which the filing identifies as a disposition to the issuer for tax withholding in connection with the vesting of Restricted Stock Units.

The first disposition involved 3,465.749 shares tied to RSUs granted on November 16, 2023, leaving Farrell with 476,419 shares directly held. The second involved 2,209.793 shares tied to RSUs granted on November 20, 2024, reducing his direct holdings to 474,209 shares. The third involved 2,435.843 shares from RSUs granted on November 20, 2025, bringing his final directly held total to 471,774 shares. All three transactions were executed at a price of $234.11 per share, as reported in the filing.

The filing notes that the 471,774 direct share figure includes 82.2684 shares acquired on October 30, 2026 through the ResMed Employee Stock Purchase Plan. In addition to his direct holdings, the filing discloses that Farrell holds 2,090 shares indirectly through the Lisette and Michael Farrell Family Trust. No derivative securities transactions were reported in Table II of the form.

What Was Disclosed

The filing disclosed three tax-withholding dispositions of ResMed common stock by Chairman and CEO Michael J. Farrell on November 11, 2026, totaling 8,111.385 shares at $234.11 per share, related to RSUs from three separate grant dates, with 471,774 shares remaining in direct ownership.